Literature DB >> 7884885

Increased adhesion as a mechanism of antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus infection.

O Lund1, J Hansen, A M Søorensen, E Mosekilde, J O Nielsen, J E Hansen.   

Abstract

Enhancement of human immunodeficiency virus (HIV) infection by complement alone or in conjunction with antibodies was studied experimentally and theoretically. Experimental studies showed that while HIV-positive sera neutralize HIV infection, the addition of fresh complement abrogated neutralization and could even cause enhancement. Enhancement was blocked by anti-complement receptor 2 antibodies, and infection under enhancing conditions could be blocked by soluble CD4. Antibody-dependent complement-mediated enhancement (C'ADE) was dependent on the alternative complement activation pathway, as factor B-deficient serum could enhance only after the addition of factor B. The observed enhancement was also antibody dependent, since the addition of antibodies increased the level of enhancement. Under C'ADE conditions, infection reached a plateau within 5 min and was not caused by activation of cells by factors in the human serum. On the contrary, preincubation of cells with complement decreased the level of enhancement. A theoretical model of HIV infection in vitro which exhibited similar enhancement in an antibody- and complement concentration-dependent way was developed. Model studies indicated that the enhanced infection process could be explained by the fact that virions, because of complement deposition on the surface, bind more efficiently to cells. The model also indicated that the saturation of the enhanced infection process seen after a few minutes could be caused by saturation of the complement receptors. The effect of neutralizing antibodies can thus be overcome by the enhancing effect of complement that facilitates the contact between gp120 and CD4. These studies demonstrate that the main features of the complement-dependent enhancement phenomenon can be understood in terms of a simple mathematical model.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7884885      PMCID: PMC188912     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

1.  Effect of anti-carbohydrate antibodies on HIV infection in a monocytic cell line (U937).

Authors:  J E Hansen; C Nielsen; H Clausen; L R Mathiesen; J O Nielsen
Journal:  Antiviral Res       Date:  1991-10       Impact factor: 5.970

2.  Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro.

Authors:  W E Robinson; M K Gorny; J Y Xu; W M Mitchell; S Zolla-Pazner
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

3.  Antibodies and complement enhance binding and uptake of HIV-1 by human monocytes.

Authors:  L J Bakker; H S Nottet; N M de Vos; L de Graaf; J A Van Strijp; M R Visser; J Verhoef
Journal:  AIDS       Date:  1992-01       Impact factor: 4.177

4.  Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus.

Authors:  S P Layne; M J Merges; M Dembo; J L Spouge; S R Conley; J P Moore; J L Raina; H Renz; H R Gelderblom; P L Nara
Journal:  Virology       Date:  1992-08       Impact factor: 3.616

5.  Functional activity of an HIV-1 neutralizing IgG human monoclonal antibody: ADCC and complement-mediated lysis.

Authors:  M R Posner; H S Elboim; T Cannon; L Cavacini; T Hideshima
Journal:  AIDS Res Hum Retroviruses       Date:  1992-05       Impact factor: 2.205

6.  Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. NIAID AIDS Vaccine Clinical Trials Network.

Authors:  D C Montefiori; B S Graham; S Kliks; P F Wright
Journal:  J Clin Immunol       Date:  1992-11       Impact factor: 8.317

7.  Phenotypic analysis of complement receptor 2+ T lymphocytes: reduced expression on CD4+ cells in HIV-infected persons.

Authors:  R A June; A L Landay; K Stefanik; T F Lint; G T Spear
Journal:  Immunology       Date:  1992-01       Impact factor: 7.397

8.  Alternative complement pathway activation by HIV infected cells: C3 fixation does not lead to complement lysis but enhances NK sensitivity.

Authors:  E Yefenof; B Asjö; E Klein
Journal:  Int Immunol       Date:  1991-04       Impact factor: 4.823

9.  CD4-independent binding of HIV-1 to the B lymphocyte receptor CR2 (CD21) in the presence of complement and antibody.

Authors:  D C Montefiori; J Zhou; D I Shaff
Journal:  Clin Exp Immunol       Date:  1992-12       Impact factor: 4.330

10.  Enhancement of human immunodeficiency virus type 1 infection by antisera to peptides from the envelope glycoproteins gp120/gp41.

Authors:  S B Jiang; K Lin; A R Neurath
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

View more
  16 in total

1.  B lymphocytes in lymph nodes and peripheral blood are important for binding immune complexes containing HIV-1.

Authors:  J J Jakubik; M Saifuddin; D M Takefman; G T Spear
Journal:  Immunology       Date:  1999-04       Impact factor: 7.397

Review 2.  The good and evil of complement activation in HIV-1 infection.

Authors:  Qigui Yu; Richard Yu; Xuebin Qin
Journal:  Cell Mol Immunol       Date:  2010-03-15       Impact factor: 11.530

3.  Association of complement receptor 2 polymorphisms with innate resistance to HIV-1 infection.

Authors:  R Herrero; L M Real; A Rivero-Juárez; J A Pineda; Á Camacho; J Macías; M Laplana; P Konieczny; F J Márquez; J C Souto; J M Soria; I Saulle; S Lo Caputo; M Biasin; A Rivero; J Fibla; A Caruz
Journal:  Genes Immun       Date:  2015-01-08       Impact factor: 2.676

Review 4.  Complement and HIV-I infection/HIV-associated neurocognitive disorders.

Authors:  Fengming Liu; Shen Dai; Jennifer Gordon; Xuebin Qin
Journal:  J Neurovirol       Date:  2014-03-18       Impact factor: 2.643

Review 5.  Follicular dendritic cells: dynamic antigen libraries.

Authors:  Balthasar A Heesters; Riley C Myers; Michael C Carroll
Journal:  Nat Rev Immunol       Date:  2014-06-20       Impact factor: 53.106

6.  Relationship between Vaccine-Induced Antibody Capture of Infectious Virus and Infection Outcomes following Repeated Low-Dose Rectal Challenges with Simian Immunodeficiency Virus SIVmac251.

Authors:  Johannes S Gach; David Venzon; Monica Vaccari; Brandon F Keele; Genoveffa Franchini; Donald N Forthal
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

7.  Role of Complement and Antibodies in the Control and Facilitation of HIV Disease.

Authors:  Zoltán Prohászka; Ferenc D Tóth; Dénes Bánhegyi; George Füst
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

8.  Antibody-mediated enhancement of parvovirus B19 uptake into endothelial cells mediated by a receptor for complement factor C1q.

Authors:  Kristina von Kietzell; Tanja Pozzuto; Regine Heilbronn; Tobias Grössl; Henry Fechner; Stefan Weger
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

9.  Association of Fcγ receptor IIIa genotype with the rate of HIV infection after gp120 vaccination.

Authors:  Donald N Forthal; Erin E Gabriel; Angela Wang; Gary Landucci; Tran B Phan
Journal:  Blood       Date:  2012-08-22       Impact factor: 22.113

10.  Antibody-dependent enhancement of hepatitis C virus infection.

Authors:  Keith Meyer; Malika Ait-Goughoulte; Zhen-Yong Keck; Steven Foung; Ranjit Ray
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.